Trinette Britt-Johnson returned home safe Saturday after days without the medication she needed for a transplanted kidney.

In any review of mifepristone, the FDA will now have to grapple with Judge Otake’s conclusion that the 2023 REMS decision for ...

With the country nearing the record for the longest government shutdown in U.S. history, the stalemate over federal funding ...

With a market cap of $455 billion, Johnson & Johnson (JNJ) is a global healthcare conglomerate headquartered in New Brunswick ...

More than 3,000 people in Britain have sued Johnson & Johnson, claiming its baby powder caused cancer, according to court ...

Shares of Johnson & Johnson were rising into record territory in early trading Tuesday, after the medicines and medical-technology giant beat quarterly earnings expectations and raised its outlook, ...

More than 3,000 U.K. claimants accuse U.S. pharmaceutical giant Johnson & Johnson of knowingly selling asbestos-tainted ...

CEO Joaquin Duato highlighted "very strong third quarter results" and described Johnson & Johnson as being in a "powerful new era of growth." The company reported operational sales growth of 5.4% and ...

Johnson & Johnson said Tuesday it plans to separate its artificial hip and knee business into a stand-alone company to be called DePuy Synthes—the latest attempt to slim down by the healthcare giant.

The orthopedics business, which generated 10% of 2024 revenue, will be separated from J&J within two years, after its consumer health business was spun off as Kenvue in 2023 Johnson & Johnson's stock ...

Breaking up isn’t so hard to do, it seems. Just two years after spinning off its consumer products as Kenvue Inc., Johnson & Johnson aims to part ways with its orthopedics unit, which will take up the ...

Johnson & Johnson is a global healthcare leader with significant scale, operating across pharmaceuticals, medtech, and consumer health segments. The company leverages strong brand recognition and a ...